Antivet

Phase 3Small molecule

CCairo University

Antivet is one of 37 small molecule programs targeting Age. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AgeNot yet recruiting

AgePhase 3

Not yet recruiting

Competition

Competitive Landscape

48 competitors in Age

#DrugCompanyPhaseTrials

Actigall

AbbVie

Approved

—2

Rapamune

PPrism Pharmaceuticals

Venclexta

3 4

Acotiamide

GGetz Pharma

Phase 3

1 5

APG-2575

Ascentage Pharma Group Inc.

Phase 2

1 6

APG-115

Ascentage Pharma Group Inc.

Phase 2

1 7

Funduscein-25

FFalcon

Phase 2

1 8

Imbruvica

PPharmacyclics LLC.

Phase 1

1 9

Antivet

CCairo University

Phase 3

1 10

Opalustre

CCairo University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Age1 trial

21% Hydrochloric Acid Based Versus 6.6 % Hydrochloric Based Micro Abrasive Kit in Management of Patients With Mild to Moderate Fluorosis

Not yet recruiting·—·Phase 4·NCT06949878·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antivet. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antivet compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antivet. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cairo University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCairo University

Antivet

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Age1 trial

References

Drug Info

Quick Facts

Related News